Reading TDOC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TDOC free→Reading TDOC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TDOC free→QuarterlyIQ Insights · TDOC
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(24.4) + peer(0.2*6.6) + term(0.0) → 9.86% (capped ±15.0)
in 48 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On April 29, 2026, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the first quarter of 2026. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On February 25, 2026, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the fourth quarter and full year 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Results of Operations and Financial Condition. On October 29, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the third quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Results of Operations and Financial Condition. On October 23, 2025, Teladoc Health, Inc. (the “Company” or “we”) issued a press release announcing preliminary results for the quarter ended September 30, 2025. These financial results are preliminary, unaudited and subject to change in connection with the completion of the Company’s financial closing process and the preparation of its financial statements for the third quarter of 2025. In addition, the Company announced that it continues to exp…
Results of Operations and Financial Condition. On July 29, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the second quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Results of Operations and Financial Condition. On April 30, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the first quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Results of Operations and Financial Condition. On February 26, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the fourth quarter and full year 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in